Edesa Biotech, Inc. (EDSA)
| Previous Close | 2.1000 |
| Open | 2.1300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.1100 - 2.2100 |
| 52 Week Range | 2.0500 - 6.4600 |
| Volume | |
| Avg. Volume | 22,837 |
| Market Cap | 7.047M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.7800 |
| Earnings Date | Dec 13, 2024 - Dec 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.50 |
GlobeNewswireEdesa Biotech’s Founder Makes Strategic Investment in the Company
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa’s Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an immediate investment of approximately $1.5 million. The entity will purch
- GlobeNewswire
Edesa Biotech Announces Upcoming Conference Schedule
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Stockholm, Sweden, November 4-6, 2024Dermatology Drug Development Summit, Boston, Mass., November 12-14, 2024LSX Investival Showcase, London, UK, November 1
